Your Health, We Care
Coadministration of Iclusig with a strong CYP3A inhibitor increases ponatinib plasma concentrations, which may increase the risk of Iclusig adverse reactions. Avoid coadministration of Iclusig with strong CYP3A inhibitors. If coadministration of Iclusig with strong CYP3A inhibitors cannot be avoided, reduce the Iclusig dosage.
Coadministration of Iclusig with a strong CYP3A inducer decreases ponatinib plasma concentrations. Avoid coadministration of Iclusig with strong CYP3A inducers unless the benefit outweighs the risk of decreased ponatinib exposure. Monitor patients for reduced efficacy. Selection of concomitant medication with no or minimal CYP3A induction potential is recommended.
FDA,2022.02
